Oxford Gene Technology (OGT), The Molecular Genetics Company,has launched two new CE-IVD labelled fluorescence in situ hybridisation (FISH) probes, further expanding its extensivelung cancer portfolio.
The Cytocell Aquarius® ROS1 PlusBreakapart and RET Breakapart probes* specifically and accurately detect rearrangements in the genome associated withthe most common form of lung cancer non-small cell lung cancer (NSCLC).The new additionscomplement OGT’s existing NSCLC probe range(including ALK Breakapart, EGFR Amplification and EML Breakapart),providing a comprehensive solution for diagnosis and patient stratification.
Lung cancer is the most commonly diagnosed cancer as well as the leading cause of cancer death in males. Worldwide, lung cancer accounted for 1.8 million new cases in 2012,1with NSCLC accounting for 85% of these.2Manisha Maurya, Clinical Scientist, Royal Marsden NHS Foundation Trust, explained the significance of the new Cytocell probes: “As NSCLC can be classified into different molecular subtypes, accurate genomic identification of the correct subtype is of paramount importance for targeted treatment. In our validation studies, the new Cytocell probes for NCSLC showed tight, bright signals allowing easy visualisation and scoring of results. These probes will further improve our ability to stratify and treat NSCLC.”
Senior Product Manager for Pathology at OGT, Steve Chatters also commented: “Cancer research is advancing at a rapid rate. At OGT, we work with leading clinical scientists to develop innovative products that utilise the latest scientific understanding. This is exemplified by our new CytocellAquarius ROS1 PlusBreakapartProbe, which has been designed to cover not only the ROS1 region but also the region deleted in ROS1-GOPC fusions, enabling more comprehensive analysis.”
The probes are available in two economical sizes and arepremixed in hybridisation buffer—saving time and minimising potential errors. Fully optimised for use on formalin-fixed, paraffin-embedded (FFPE) samples, Cytocell FISH probes deliver high-intensity signals with minimal background for accurate, reliable results and confident diagnoses.
Download OGT’s new brochure at www.ogt.com/NSCLC to find out more about the extensive range of Cytocell FISH probes for NSCLC.
1. Ervik M, et al (2016) Cancer Today. Lyon, France: International Agency for Research on Cancer. Cancer Today. Available from: http://gco.iarc.fr/today, accessed 30/08/2016
2. Molina JR, et al (2008) Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic proceedings Mayo Clinic. 83(5):584-594
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road,Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
* Cytocell Aquarius® RET Breakapart and ROS1 PlusBreakapartprobes have received the CE-IVD label, and will be available from 8th September 2016.
ytoSure™, SureSeq™ and myProbes®: For Research Use Only; Not for Use in Diagnostic Procedures. Cytocell: Some products may not be available in the US.
Dr. Paul Chang, MD, MBA, MPH, CPHQ, FACHE, Vice President, Accreditation, Standards and Measurement, Joint Commission International.
Dr. Paul Chang is Vice President of Accreditation, Standards, and Measurement. In this capacity, he leads a global team of talented and dedicated accreditation professionals to serve health care organizations throughout the world.
In prior positions, he served in a variety of roles in the Singapore Ministry of Health. Later, Dr. Chang oversaw clinical quality, risk management, quality improvement, and JCI accreditation at Changi General Hospital, an 800-bed Singaporean public hospital. He was part of the management team that led the hospital to achieve JCI accreditation in 2005 and JCI disease-specific certification in two cardiology programs (Acute Myocardial Infarction and Heart Failure) in 2007.
He went on to serve as JCI’s Asia-Pacific office Managing Director from 2007 to 2013. While in the Asia-Pacific region, Dr. Chang collaborated with regional ministries of health, governmental and nongovernmental agencies, hospitals, laboratories, and various health care organizations to develop ways to improve health outcomes and patient safety. In 2013, he joined JCI’s executive team as Senior Executive Director of Accreditation and Standards prior to assuming his current role.
Dr. Chang earned his medical degree and a Master of Public Health from the National University of Singapore and an MBA from the UCLA Anderson School of Management. He is a trained JCI accreditation and International Society for Quality in Healthcare (ISQua) surveyor.
Hope you are doing good!
Please find the link to the video interview shoot with Ms. Michelle Troseth mentioned below for your perusal:
Sorry for the delay as the interview was shot on a lunch break with lot of cups and plates breaking in the background, we have tried to reduce the voice to the best in the background.
The video is without the proof read and we could further refine for minor changes. We could do this once you approve the same.
There are 3 files in the link 2 are the original shoot and the other to be a high resolution MP4 file (customised).
Please help me know your feedback on the same and feel free to contact for any further queries you may have.
Editor | Hospital & Healthcare Management
M: +91 84476 12124 | E: mailto:email@example.com
Dr Peter Edelstein who is the Chief Medical Officer of Elsevier Clinical Solutions answers on how better patient outcomes could be achieved through Clinical Practice Guidelines (CPGs) along with the challenges and solutions towards Implementation of (CPGs) by the providers to improve quality of care.